BioMedReports Blog | Talkmarkets | Page 1
Biotech Investing, Healthcare Stocks
Contributor's Links: BioMedReports

BioMedReports.com was co-founded by M.E. Garza and Mike Havrilla in early 2009. Both were successful traders and investors who had historically made some of their more

Articles

Latest Posts
1 to 16 of 77 Posts
1 2 3 ... 5
PTBI Announces Initiation Of Enrollment Of MuGard® Trial For Afinitor®; IRWD Initiates Phase I Clinical Study Of IW-1973
PTBI, announced enrollment has begun in a clinical trial at UCLA's Jonsson Comprehensive Cancer Center. IRWD announced dosing has begun in a Phase I clinical study of IW-1973, the first clinical compound in a broad.
ADMP Announces Positive Results For Its Dry Powder Inhaler Product; BOTA Commences Dosing In Vapendavir Phase 2b Trial
ADMP announced the results of its pharmacokinetic (PK) study for its dry powder inhaler product, APC-5000. BOTA announced it has commenced dosing of patients in its Phase 2b SPIRITUS trial of vapendavir.
Rigel Pharmaceuticals, Inc. Surges 39% On Agreement With Bristol-Myers Squibb
Following the surge in stock price, here is what you need to know about Rigel's latest development.
NEPT Shareholders Approve Arrangement With Neptune; Aileron Initiates Phase 1 Cancer Study Of ALRN-6924
NEPT shareholders (the "Shareholders") approved a resolution today authorizing the previously announced plan of arrangement providing for, among other things, the indirect acquisition by Neptune of all of the issued and outstanding shares of NeuroBio.
Advaxis, Inc. Surges 9% On Collaboration With Incyte Corporation
Shares of Advaxis, Inc. jumped 9% to $7.70 after the company entered into a clinical trial collaboration with Incyte Corporation.
PFNX In Development Pact For Macular Degeneration Drug; KYTH Acquires Worldwide Rights To Potential Novel Treatment Of Hair Loss
Pfenex Inc. In Development Pact For Macular Degeneration Drug, KYTHERA Acquires Worldwide Rights to Potential Novel Treatment of Hair Loss
Anthera Pharmaceuticals Inc (ANTH) Gains 35% On Phase 3 Trial Update
Anthera Pharmaceuticals Inc. (ANTH) jumped a whopping 35% to $3.53 this afternoon on huge volume of 13.04 million shares as the company announced that its Phase 3 trials will continue to completion as planned.
Provectus Biopharmaceuticals Concludes FDA Meeting For PV-10 Phase 3; Successful Completion Of AB Science's Futility Test For Masitinib
Here is a look at some of the headlines for companies that made news in the healthcare sector on February 9, 2015.
Achillion Pharmaceuticals, Inc. Shares Rebound On Positive Development
Company reports excellent results in combination against Hepatitis-C virus.
Aclaris Announces Positive Results From Phase 2b Clinical Trial Of A-101; FDA Accepts CTDH Drug Master File
Aclaris Therapeutics, Inc. announced positive results from a Phase 2b clinical trial of the Company’s lead drug, A-101.
ATNM Submits CMC Meeting Request To FDA For Iomab-B; NBIX Announces Oral Presentation Of NBI-77860 Clinical Trial Data
ATNM announced that it has submitted a request for a CMC meeting to the U.S. Food and Drug Administration (FDA) for the company's Iomab-B drug. NBIX announced the steering committee of ENDO 2015 has selected the abstract of their recently completed clinical study of NBI-77860.
Depomed To Acquire U.S. Rights To NUCYNTA®, NUCYNTA® ER; Amgen Presents First-Line Use Of Vectibix®
Depomed Inc. announced it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion.
EnteroMedics Spikes Up Following FDA Approval Of Neuroblocking Obesity Device
Also, pSivida Corp. announces sales of Iluvien for diabetic macular edema has begun in Portugal.
NRX Received Positive Scientific Advice For Phase 3 Program In Diabetic Nephropathy
NRX has announced that the Company has received positive Scientific Advice from the European Medicines Agency (EMA) regarding their Phase 3 program with Pyridorin® in diabetic nephropathy.
Minerva Neurosciences Hits An All Time High After A Positive Development
Compound shows promising results on Parkinson's in primates.
Cerus Corporation Jumps Following Clinical Update
Cerus Corporation shares jumped 4% after the company announced that the haemoglobin content (53.1g) of INTERCEPT content treated red blood cell components (RBCs).
1 to 16 of 77 Posts
1 2 3 ... 5